Quantcast

Latest Histone deacetylase inhibitor Stories

2014-07-23 23:22:00

Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/histone-deacetylase-inhibitors.html. (PRWEB) July 22, 2014 Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by...

2014-06-17 08:29:08

SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration as a treatment for myelodysplastic syndrome (MDS). Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with...

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-04-07 08:31:12

New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new pre-clinical data showing the ability of its lead drug candidate Pracinostat to inhibit bladder cancer cell growth and induce activated transcription factor 3 (ATF-3) expression, a potential marker of tumor response. The data...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2014-02-26 23:22:59

The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018. Wellesley, Mass. (PRWEB) February 26, 2014 According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research (http://www.bccresearch.com), the...

2014-02-24 23:26:06

Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) February 24, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article in the Journal of Photochemistry and Photobiology detailing a promising new treatment for people with cutaneous T-cell lymphoma (CTCL), a variety of T-cell Non-Hodgkin’s Lymphoma involving the skin. Patients...

2014-02-05 23:23:28

Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Downingtown, PA (PRWEB) February 05, 2014 Repligen Corporation announced that BioMarin Pharmaceutical has acquired the assets in the company’s Histone DeACetylase (HDAC) inhibitor program. Repligen has been advancing a therapeutic research and development program in Friedreich's Ataxia (FA) in which specific HDAC inhibitors have been...

2014-01-27 04:21:37

DUBLIN, January 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/g3pk2m/epigenetics_drugs) has announced the addition of the "2013 Report on the International Epigenetics Drugs and Diagnostic Technologies Market - Trends And Forecasts to 2018" [http://www.researchandmarkets.com/research/g3pk2m/epigenetics_drugs ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) "2013 Report on the...

2013-12-11 13:14:42

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University’s Kimmel Cancer Center. The finding, published in the October issue of the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related